Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that, further to its news release dated December 19, 2017, the Company has closed the first tranche of its non-brokered private placement (the “Offering”) for $20,000,000 CAD by issuing 16,000,000 units (“Units”) at a price of $1.25 per unit.

Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that, further to its news release dated December 19, 2017, the Company has closed the first tranche of its non-brokered private placement (the “Offering”) for $20,000,000 CAD by issuing 16,000,000 units (“Units”) at a price of $1.25 per unit.

“With this capital, we now have the utmost flexibility to continue our aggressive pursuits of global expansion, as well as the ability to pursue additional strategic acquisitions,” said Marcos Agramont, CEO of Isodiol. “Overall, this capital will be critical in achieving our vision of becoming the global leader in providing pharmaceutical grade phytoceuticals and as we head into 2018, we will continue to be relentless in our efforts to grow and expand our business.”

The Company anticipates the second tranche to be closed by Friday, December 22, 2017.

With respect to the Offering, each Unit will comprise one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $2.00 for a period of twenty-four (24) months from the closing of the Offering.

The securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance pursuant to applicable securities laws. The Company has paid certain eligible persons (the “Finders”) a cash commission equal to 6% of the proceeds raised from subscribers introduced to the Offering by such Finders and also issued broker warrants (the “Broker Warrants”) equal to 6% of the securities purchased by such subscribers.

For more information on Isodiol, please visit www.isodiol.com.
About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.

Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.

Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
604-409-4409
marcos@isodiol.com
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
Click here to connect with Isodiol International LLC (CSE:ISOL, OTC:LAGBF, FSE:LBGA.F) for an Investor Presentation.